Inhibition of c-Jun/Bak Signaling Alleviates Endothelial Cell Senescence and Inflammation Caused by Mitochondrial Dysfunction in DMED

Rat study identifies a molecular pathway linking high blood sugar to penile endothelial aging — no human data yet

Journal: Archives of Gerontology and Geriatrics | Published: 2025-12-16 | Type: Journal Article | PMID: 41453296 Authors: Jianxiong Ma, Yingxue Guo, Zeng Zhongliao, Li Yuyi, Jie Huang, Qiang He (Zhejiang Chinese Medical University affiliates; one author from Zhejiang University School of Medicine) Funding/COI: Funding not disclosed. Authors declare no competing interests.

Summary

Diabetic erectile dysfunction (DMED) is thought to begin with damage to the endothelial cells lining penile blood vessels, but the molecular mechanism has been poorly characterized. This study used single-cell RNA sequencing and transcriptomic analysis to identify the c-Jun/Bak pathway as a driver of endothelial cell senescence and inflammation under high-glucose conditions in both DMED rats and in vitro models. When JNK (the kinase that activates c-Jun) was inhibited, mitochondrial function improved and senescence markers dropped; when Bak was artificially activated, those benefits disappeared. The authors themselves flag significant translational uncertainty — this is mechanistic groundwork in rodents, not a path to clinical application.

Claims

• Single-cell RNA sequencing of DMED tissue identified c-Jun/Bak signaling as a top-ranked pathway in dysfunctional penile endothelial cells
• Hyperglucose exposure activated c-Jun/Bak, producing measurable mitochondrial structural damage, excessive reactive oxygen species (ROS), and metabolic dysfunction in vitro
• Penile corpus cavernosal endothelial cells in DMED rats showed elevated senescence markers (specific markers not quantified in the abstract) alongside JNK overactivation
• JNK inhibition in vitro attenuated both aging-associated markers and inflammatory signaling; Bak overactivation reversed these effects, confirming pathway specificity
• Authors propose c-Jun/Bak-mediated mitochondrial regulation as a "novel therapeutic target" for DMED

Study Quality

This is a mechanistic animal and cell study — it is not designed to demonstrate clinical efficacy and should not be read as doing so. The methodological toolkit is solid for the question being asked: scRNA-seq provides single-cell resolution on pathway activity, and the in vitro rescue/reversal experiments (JNK inhibition vs. Bak activation) provide reasonable mechanistic confirmation. Establishing that Bak activation reverses the benefits of JNK inhibition is useful — it tightens the causal chain rather than leaving it at correlation.

However, the abstract provides no specific quantitative outcomes: no fold-changes in senescence markers, no ROS measurements, no intracavernosal pressure data from the rat model. That makes independent quality assessment of the actual results impossible without reading the full paper. The rat model of diabetes-induced ED is a recognized research tool, but penile vascular biology in rodents differs meaningfully from humans, and the authors acknowledge this directly.

Red Flags

• No funding disclosure. For a paper from a Chinese medical university publishing in a Western aging journal, the absence of any grant acknowledgment is unusual and limits accountability
• No quantitative data in abstract. Zero numbers reported — no effect sizes, no statistical values, no sample sizes for either the animal cohort or cell experiments
• Pure mechanistic study marketed as therapeutic. The conclusion frames c-Jun/Bak as a "therapeutic target," but this paper establishes mechanism in rats; the gap to human treatment is vast and largely unaddressed
• Journal fit is questionable. Archives of Gerontology and Geriatrics is a geriatric medicine journal; DMED mechanism work would more naturally land in andrology, urology, or vascular biology journals — raising the question of where this was submitted first
• Translational complexity self-acknowledged but underweighted. The abstract's one-sentence caveat about "translational challenges" understates how far this work is from clinical relevance

Strengths

• scRNA-seq is an appropriate and modern tool for pathway discovery in heterogeneous tissue; it's not being misapplied here
• The bidirectional experimental design (inhibit JNK → improvement; activate Bak → reversal) strengthens mechanistic inference compared to one-directional studies
• Focusing on endothelial senescence as a DMED mechanism is a legitimate and underexplored angle — most ED research targets smooth muscle or neurogenic pathways
• Authors are transparent about the human-rodent translational gap, which is more than many mechanistic papers concede

Verdict

This is early-stage mechanistic work in rats and cells that identifies a plausible molecular pathway — c-Jun/Bak-driven mitochondrial dysfunction — contributing to endothelial aging in diabetic ED. The experimental design is competent for what it is. But the complete absence of quantitative data in the abstract, the missing funding disclosure, and the aggressive therapeutic framing of what is fundamentally a rodent pathway study are all reasons to hold this lightly. File it as hypothesis-generating. If a larger, funded research group replicates the pathway finding in human tissue or produces a JNK inhibitor trial, that would be news. This paper alone is not.